
Sign up to save your podcasts
Or


Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:
By JAMA Network4.6
162162 ratings
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic's Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content:

6,748 Listeners

43,732 Listeners

38,676 Listeners

21,628 Listeners

137 Listeners

320 Listeners

700 Listeners

497 Listeners

759 Listeners

885 Listeners

3,343 Listeners

21 Listeners

12 Listeners

16 Listeners

7 Listeners

19 Listeners

29 Listeners

195 Listeners

90 Listeners

364 Listeners

6,420 Listeners

19 Listeners